Kancera AB (Nasdaq First North Premier Growth Market: KAN) today announces that results from the Phase Ib program for KAND567 show that the drug candidate is well tolerated by intravenous administration. Kancera will now compile an application for permission to start a...
Read MoreThis is a translation of the report in Swedish.
Read MoreKancera AB (Nasdaq First North Premier Growth Market: KAN) today announces that it has received approval from the Finnish Medicines Agency Fimea and the Ethics Committee to start the final part of the phase Ib program for KAND567. The company estimates that...
Read MoreKancera AB (Nasdaq First North Growth Market: KAN) reports results from an in-depth immunological analysis of blood samples from healthy subjects in the ongoing Phase Ib program. The analysis shows that KAND567 effectively blocks certain specific immune cells that are known to...
Read MoreThird quarter in brief 1 July – 30 September 2019 Net sales for the period (January to September) amounted to SEK 3,3 Million (0,1 Million) of which the third quarter contributed SEK 0,2 Million (0,0 Million). R&D costs for...
Read MoreThis is a translation of a press release in Swedish published in Stockholm 2019-11-22 Kancera AB (Nasdaq First North Growth Market: KAN) and Grünenthal work together to develop HDAC inhibitors for the treatment of pain and inflammation. The companies have now decided...
Read MoreThis is a translation of a press release in Swedish published 2019-11-21 Kancera AB (Nasdaq First North Growth Market: KAN) today announces that the company intends to complete the final phase of the Phase Ib study of the drug candidate KAND567 in...
Read MoreKancera AB (Nasdaq First North: KAN) announces the first public presentation of data for KAND567, its fractalkine receptor antagonist, in preclinical models of cardiovascular disease and its predicted translation to humans at the European Society of Cardiology (ESC) Congress 2019 in Paris,...
Read MoreKancera today announces that a further developed dosing strategy is intended to be tested for the treatment with KAND567. The reason is that the modified intravenous dosing studied in the phase Ib study in August 2019 resulted in a clearly improved but...
Read MoreSecond quarter in brief 1 April – 30 June 2019 Net sales for the period (January to June) amounted to SEK 3,1 Million (0 Million) of which the second quarter contributed SEK 0 Million (0 Million). R&D costs for...
Read More